Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

Change in PDL Status for the Atopic Dermatitis Immunomodulator Pimecrolimus and the Anti-Inflammatory Ophthalmic Loteprednol Etabonate Effective April 4, 2025

Last updated on

On April 4, 2025, the Texas Health and Human Services Commission (HHSC) removed the authorized generic pimecrolimus 1% cream and generic loteprednol etabonate 0.5% eye drop suspension products from the HHSC preferred drug list (PDL). This change is in response to the confirmed drug shortage of preferred brand name Elidel 1% cream (pimecrolimus) and drug discontinuation of the preferred brand name Lotemax 0.5% eye drop suspension (loteprednol etabonate 0.5%).

The non-preferred status has been removed from the following drugs:

National Drug Code (NDC)Drug Name
68682011001Pimecrolimus 1% cream (authorized generic)
68682011102Pimecrolimus 1% cream (authorized generic)
68682011203Pimecrolimus 1% cream (authorized generic)
62756023255Loteprednol elabonate 0.5% drops (generic)
62756023256Loteprednol elabonate 0.5% drops (generic)
62756023290Loteprednol elabonate 0.5% drops (generic)
68682029905Loteprednol elabonate 0.5% drops (generic)
68682029910Loteprednol elabonate 0.5% drops (generic)
68682029915Loteprednol elabonate 0.5% drops (generic)
72603032401Loteprednol elabonate 0.5% drops (generic)
72603032402Loteprednol elabonate 0.5% drops (generic)
72603032403Loteprednol elabonate 0.5% drops (generic)
72485066505Loteprednol elabonate 0.5% drops (generic)

These changes allow providers to prescribe the authorized generic pimecrolimus 1% cream and generic loteprednol etabonate 0.5% eye drop suspension products without requiring PDL prior authorization. 

Email vdp-formulary@hhsc.state.tx.us with any questions.